Intellia Therapeutics (NASDAQ:NTLA) Given New $14.00 Price Target at Barclays

Intellia Therapeutics (NASDAQ:NTLA) had its price objective decreased by Barclays from $24.00 to $14.00 in a report issued on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other brokerages also recently commented on NTLA. Tudor Pickering set a $14.50 target price on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $60.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Citizens Jmp decreased their target price on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a research note on Friday. Finally, Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 6th. Twelve equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.39.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA traded down $2.80 during mid-day trading on Friday, hitting $9.52. The company had a trading volume of 25,372,622 shares, compared to its average volume of 10,223,058. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The firm has a market cap of $1.02 billion, a P/E ratio of -2.23 and a beta of 2.44. The business’s fifty day moving average is $17.19 and its two-hundred day moving average is $12.47.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 56.28% and a negative net margin of 774.94%.The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.34) EPS. Equities analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. The trade was a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William J. Chase bought 100,000 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the acquisition, the director directly owned 134,693 shares of the company’s stock, valued at $1,350,970.79. The trade was a 288.24% increase in their position. The SEC filing for this purchase provides additional information. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Blue Bell Private Wealth Management LLC acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $30,000. Headlands Technologies LLC bought a new stake in Intellia Therapeutics during the second quarter worth about $26,000. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after purchasing an additional 927 shares during the last quarter. Whipplewood Advisors LLC grew its stake in Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after purchasing an additional 3,447 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after purchasing an additional 1,655 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.